BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology.
Our company focuses on the development of products for treatment of metabolic diseases and various immuno-therapies.
In terms of diabetes, our lead molecules are an oral "biobetter" of liraglutide and exenatide (GLP-1) in type II diabetes. In addition to that, we are developing a combination product of insulin+GLP1.
We are also exploring the use of low dose IL-2 for early onset juvenile type I diabetes. Low dose IL-2 in animal models has shown to balance Treg and Teff immune cells to reverse or prevent type I diabetes. Especially in children, having an oral therapy will make a difference.
A second area of interest is immuno-therapy, since sublingual administration facilitates targeting the lymphatic system directly.
We have some good data with IL-2 immunotherapy in arthritis, psoriasis, diabetes type 1, peanut allergy and cancer. We believe that this effect is due to altering the balance of Tregs.
Sublingual administration can increase efficacy and/or reduce side-effects compared to administration by injection.
Our technology can also stabilize proteins and peptides to prevent degradation and this is for use in third world countries by :
- reducing the need for a cold chain
- preventing the risk of infections due to needle handling (e.g. HIV and HCV).
As such, we can “broaden access” for patients in third world countries, which is an important goal for WHO.
Because of the specific properties of our technology, it is applicable to a broad range of molecules, as shown in the diagram below :